Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas. Show more

Location: 1017 Ranch Road 620 South, Lakeway, TX, 78734, United States | Website: https://www.anebulo.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

68.2M

52 Wk Range

$0.80 - $3.08

Previous Close

$1.77

Open

$1.73

Volume

1,052

Day Range

$1.66 - $1.73

Enterprise Value

45.88M

Cash

13.28M

Avg Qtr Burn

-1.688M

Insider Ownership

40.54%

Institutional Own.

55.05%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Selonabant (ANEB-001) Details Cannabinoid intoxication	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IV Selonabant (ANEB-001) Details Cannabinoid intoxication	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.